Scleritis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Anterior Scleritis (Diffuse Scleritis, Nodular Scleritis, and Necrotizing Scleritis), Posterior Scleritis, and Others),  By Diagnostic Test (Ultrasonography, Complete Blood Count, Biopsy, and Others), By Treatment (Medication (Corticosteroid, Nonsteroidal Anti-Inflammatory Drugs, and Immunosuppressive Drugs) and Surgery), By End User (Hospitals & Clinics, Diagnostic Centers, and Academic & Research Organizations) and Region Forecast 2020-2031

Scleritis Market size was valued at US$ 3.42 billion in 2024 and is expected to reach US$ 5.07 billion by 2031, growing at a significant CAGR of 5.8% from 2025-2031. Scleritis is a medical condition where inflammation occurs in episcleral and scleral tissues with injection in both superficial and deep episcleral vessels. It is reported to cause damage to the cornea, adjacent episclera, and the uvea and thus can be vision-threatening. Scleritis is often associated with an underlying systemic disease in up to 50% of patients and is linked to autoimmune diseases when the body's immune system attacks and destroys healthy body tissue. For example, rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases.

According to a report, out of every 100,000 people, 71 are diagnosed with rheumatoid arthritis each year and around 1.5 million Americans have rheumatoid arthritis. Women are about two to three times more likely to get rheumatoid arthritis than men. The growing geriatric population and increasing per capita income in economic countries, healthcare expenditure, new diagnostic tools, and new therapies invention will drive the overall market growth. Along with that, the rising prevalence of arthritis, technological advancements in treatment and diagnosis, and the rising incidence of eye diseases will also boost market growth.

According to a report, of 217 061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were confirmed. The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) and 21.7 (95% CI: 17.7-26.5) cases per 100 000 person-years, respectively. Women were overrepresented among scleritis patients (P = .049). Hence, the market is expected to maintain its growth during the forecasted years. However, lack of awareness and the absence of targeted treatment and therapies are expected to hinder the market growth during the forecast period.

Key Developments:

In Oct 2020, U.S. Food and Drug Administration approved Opdivo (nivolumab) and Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma